BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2025 5:57:32 AM | Browse: 76 | Download: 336
 |
Received |
|
2024-08-14 02:12 |
|
Peer-Review Started |
|
2024-08-05 18:15 |
|
First Decision by Editorial Office Director |
|
2024-12-11 06:48 |
|
Return for Revision |
|
2024-12-11 06:48 |
|
Revised |
|
2025-02-23 23:23 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-04-16 02:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-04-16 07:32 |
|
Articles in Press |
|
2025-04-16 07:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-05-30 12:57 |
|
Publish the Manuscript Online |
|
2025-11-19 05:57 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alissar El Chediak, Dhruv Ahuja, Cassandra Bruns, Rachael Simard, Kellie Spence, Amna Gul, Rachel C Forbes and Beatrice P Concepcion |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Beatrice P Concepcion, Associate Professor, MD, Department of Medicine, Section of Nephrology, University of Chicago, 5841 S. Maryland Ave
MC 5100, Chicago, IL 60637, United States. beatrice.concepcion@bsd.uchicago.edu |
| Key Words |
Pre-exposure prophylaxis; kidney transplant; COVID-19; SARS-CoV-2; tixagevimab/cilgavimab; Early posttransplant period |
| Core Tip |
This study reports on the use of tixagevimab/cilgavimab in newly transplanted kidney recipients. There were no adverse events related to the drug, and a 12.5% breakthrough infection rate, 4.5% hospitalization rate, and no deaths. The results suggest reassuring outcomes in newly transplanted kidney recipients who received tixagevimab/cilgavimab 300 mg/300 mg as prevention for coronavirus disease 2019 during the omicron wave. A systematic literature review of studies reporting outcomes of solid organ transplant recipients who received tixagevimab/cilgavimab found that the drug was well tolerated and a higher dose (300 mg/300 mg) was more protective against breakthrough infections and hospitalization than the lower dose (150 mg/150 mg). |
| Publish Date |
2025-11-19 05:57 |
| Citation |
El Chediak A, Ahuja D, Bruns C, Simard R, Spence K, Gul A, Forbes RC, Concepcion BP. Prophylactic role of tixagevimab/cilgavimab for COVID-19 in newly transplanted kidney recipients: Single-center experience and review of literature. World J Transplant 2025; 15(4): 100041 |
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i4/100041.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i4.100041 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
